Breakthrough Breast Cancer's Comment On New Targeted Antibody Therapy For Advanced Her2-Positive Breast Cancer
Main Category: Breast CancerAlso Included In: Cancer / Oncology; Women's Health / Gynecology
Article Date: 02 Jun 2009 - 4:00 PDT
email to a friend 
printer friendly 
view / write opinions 
rate article|
|
Current Article Ratings:
| Patient / Public: |  |
|
| Health Professional: |  |
3 (1 votes) |
| Article Opinions: | 0 posts |
Dr Alexis Willett, Head of Policy & Involvement at Breakthrough Breast Cancer, says:
"This study suggests that patients with HER2 positive advanced breast cancer who are no longer responding to Herceptin or chemotherapy may benefit from the combined Herceptin and DM1 treatment. Whilst many patients responded to the treatment in this trial, further larger studies will be needed to assess the full benefits.
"There are limited treatments available for those with advanced breast cancer so improving the range of options is always welcome and we look forward to the results of the ongoing trials of this treatment."
Source
Breakthrough Breast Cancer
View drug information on Herceptin.
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Breast Cancer headlines email to a friend printer friendly version
weekly newsletter daily news alerts
personalize your news
rss feeds
back to top
|
|
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |
